The evidence that the retinal circulatory response to diffuse flickering light is related to endothelial function
22 is based on the documented role of NO in flickering light–induced vasodilation.
18–21 In a study by Dorner et al.,
18 N G-monomethyl-
l-arginine (LNMMA), an inhibitor of NO synthase, blunted this flicker-induced vasodilation in healthy individuals. Furthermore, impaired response to light-flicker stimulation in persons with hypertension could be restored by angiotensin-II subtype 1 receptor blockade,
26 similar to a recent study in which improvement was found in the retinal arteriolar architecture with successful treatment of hypertension.
27 However, these were documented only in persons without diabetes, and the mechanisms may differ. For example, it has been demonstrated that systemic administration of valsartan (angiotensin II type 1 receptor blockers) has little effect on the retinal blood flow in healthy humans,
28 whereas treatment with either an angiotensin-converting enzyme inhibitor or an angiotensin II type 1 receptor blocker normalized retinal blood flow in diabetic rats.
29 In addition, there may be an endothelium-independent component to this flicker response, as the impaired vasodilatory response of the microcirculation that has been demonstrated in other vascular beds is both endothelium-dependent and -independent.
30 In addition, it is becoming increasingly clear that neuronal cells of the retina are also affected by diabetes, resulting in dysfunction and degeneration.
31 As retinal blood flow is coupled with neuronal activity,
32 reduced flicker-induced vasodilation can thus reflect neurodegeneration as well.
23,33 Therefore, in persons with diabetes, reduced flicker-induced vasodilation may reflect damage to both the neural tissues and the microcirculation in diabetes.